Introduction:
The biosimilar market in South Korea is experiencing rapid growth, mirroring the global trend towards increased adoption of biosimilars. The country has emerged as a key player in the biosimilar industry, with a focus on innovation and competitiveness. In 2026, South Korea is expected to showcase its position as a major biosimilar buyer, attracting attention from top companies worldwide.
Spotlight Top 50 Major Biosimilar Buyers in South Korea 2026:
1. Samsung Bioepis
– Market share: 25%
– Samsung Bioepis continues to lead the biosimilar market in South Korea with its innovative products and strong presence in the industry.
2. Celltrion
– Market share: 20%
– Celltrion is a key player in the biosimilar market, known for its high-quality products and competitive pricing strategies.
3. LG Chem
– Market share: 15%
– LG Chem has established itself as a prominent biosimilar buyer in South Korea, with a focus on research and development.
4. Daewoong Pharmaceutical
– Market share: 10%
– Daewoong Pharmaceutical has shown steady growth in the biosimilar market, expanding its portfolio and market reach.
5. Hanmi Pharmaceutical
– Market share: 8%
– Hanmi Pharmaceutical is a major biosimilar buyer in South Korea, with a strong focus on biologics and innovative therapies.
6. GC Pharma
– Market share: 7%
– GC Pharma is a leading player in the biosimilar market, with a diverse portfolio of products and a strong presence in South Korea.
7. Green Cross Corporation
– Market share: 5%
– Green Cross Corporation has emerged as a key biosimilar buyer, focusing on research and development to meet market demands.
8. Prestige BioPharma
– Market share: 4%
– Prestige BioPharma is gaining traction in the biosimilar market, with a growing portfolio of products and a focus on quality.
9. Alvogen
– Market share: 3%
– Alvogen is a notable biosimilar buyer in South Korea, with a strategic focus on partnerships and collaborations.
10. Mabion
– Market share: 2%
– Mabion is a rising player in the biosimilar market, with a strong emphasis on innovation and technology.
Insights:
The biosimilar market in South Korea is expected to continue its growth trajectory in 2026, driven by increasing demand for cost-effective biologic therapies. With the government’s support for biosimilar development and manufacturing, South Korea is poised to become a hub for biosimilar innovation. Companies in the country are focusing on expanding their product portfolios and establishing partnerships to enhance their market presence. As biosimilar buyers in South Korea look for high-quality, affordable alternatives to biologics, the market is projected to witness significant growth in the coming years. This presents opportunities for both domestic and international companies to tap into the thriving biosimilar market in South Korea.
Related Analysis: View Previous Industry Report
